Total Payments
$2.1M
2024 Payments
$336,565
Companies
22
Transactions
1,612
Medicare Patients
1,353
Medicare Billing
$305,020
Payment Breakdown by Category
Other$1.6M (75.6%)
Consulting$251,813 (12.1%)
Travel$208,691 (10.0%)
Food & Beverage$41,394 (2.0%)
Education$4,175 (0.2%)
Research$1,266 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.5M | 476 | 73.8% |
| Consulting Fee | $251,813 | 79 | 12.1% |
| Travel and Lodging | $208,691 | 510 | 10.0% |
| Food and Beverage | $41,394 | 511 | 2.0% |
| Compensation for serving as faculty or as a speaker for a medical education program | $32,600 | 14 | 1.6% |
| Honoraria | $4,200 | 2 | 0.2% |
| Education | $4,175 | 10 | 0.2% |
| Unspecified | $1,266 | 10 | 0.1% |
Payments by Type
General
$2.1M
1,602 transactions
Research
$1,266
10 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $698,143 | 526 | $0 (2024) |
| GlaxoSmithKline, LLC. | $415,258 | 238 | $0 (2024) |
| TESARO, Inc. | $204,720 | 235 | $0 (2019) |
| Clovis Oncology, Inc. | $174,975 | 165 | $0 (2021) |
| Eisai Inc. | $121,497 | 74 | $0 (2024) |
| Merck Sharp & Dohme LLC | $118,623 | 132 | $0 (2024) |
| Genentech USA, Inc. | $91,075 | 69 | $0 (2019) |
| Seagen Inc. | $75,223 | 41 | $0 (2023) |
| ABBVIE INC. | $51,885 | 29 | $0 (2024) |
| Genmab U.S., Inc. | $47,161 | 23 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $336,565 | 188 | GlaxoSmithKline, LLC. ($93,341) |
| 2023 | $280,598 | 169 | GlaxoSmithKline, LLC. ($104,978) |
| 2022 | $278,867 | 185 | GlaxoSmithKline, LLC. ($108,374) |
| 2021 | $193,807 | 109 | AstraZeneca Pharmaceuticals LP ($82,235) |
| 2020 | $113,496 | 98 | AstraZeneca Pharmaceuticals LP ($51,081) |
| 2019 | $425,439 | 408 | AstraZeneca Pharmaceuticals LP ($144,424) |
| 2018 | $256,257 | 258 | AstraZeneca Pharmaceuticals LP ($95,147) |
| 2017 | $193,368 | 197 | AstraZeneca Pharmaceuticals LP ($61,029) |
All Payment Transactions
1,612 individual payment records from CMS Open Payments — Page 1 of 65
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,740.00 | General |
| Category: Oncology | ||||||
| 12/30/2024 | GlaxoSmithKline, LLC. | JEMPERLI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,350.00 | General |
| Category: ONCOLOGY | ||||||
| 12/19/2024 | ABBVIE INC. | ELAHERE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,504.00 | General |
| Category: ONCOLOGY | ||||||
| 12/19/2024 | ABBVIE INC. | ELAHERE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,504.00 | General |
| Category: ONCOLOGY | ||||||
| 12/19/2024 | ABBVIE INC. | ELAHERE (Drug) | Travel and Lodging | In-kind items and services | $750.69 | General |
| Category: ONCOLOGY | ||||||
| 12/19/2024 | ABBVIE INC. | ELAHERE (Drug) | Travel and Lodging | In-kind items and services | $271.48 | General |
| Category: ONCOLOGY | ||||||
| 12/19/2024 | ABBVIE INC. | ELAHERE (Drug) | Food and Beverage | In-kind items and services | $121.82 | General |
| Category: ONCOLOGY | ||||||
| 12/19/2024 | ABBVIE INC. | ELAHERE (Drug) | Food and Beverage | In-kind items and services | $28.35 | General |
| Category: ONCOLOGY | ||||||
| 12/18/2024 | GlaxoSmithKline, LLC. | ZEJULA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,350.00 | General |
| Category: ONCOLOGY | ||||||
| 12/18/2024 | GlaxoSmithKline, LLC. | JEMPERLI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,350.00 | General |
| Category: ONCOLOGY | ||||||
| 12/18/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $128.77 | General |
| Category: Oncology | ||||||
| 12/17/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,640.00 | General |
| Category: Oncology | ||||||
| 12/17/2024 | GlaxoSmithKline, LLC. | ZEJULA (Drug) | Travel and Lodging | In-kind items and services | $198.10 | General |
| Category: ONCOLOGY | ||||||
| 12/17/2024 | GlaxoSmithKline, LLC. | ZEJULA (Drug) | Food and Beverage | In-kind items and services | $98.57 | General |
| Category: ONCOLOGY | ||||||
| 12/12/2024 | GlaxoSmithKline, LLC. | ZEJULA (Drug) | Travel and Lodging | In-kind items and services | $676.80 | General |
| Category: ONCOLOGY | ||||||
| 12/12/2024 | GlaxoSmithKline, LLC. | ZEJULA (Drug) | Food and Beverage | In-kind items and services | $112.35 | General |
| Category: ONCOLOGY | ||||||
| 12/11/2024 | GlaxoSmithKline, LLC. | ZEJULA (Drug) | Travel and Lodging | In-kind items and services | $444.94 | General |
| Category: ONCOLOGY | ||||||
| 12/11/2024 | GlaxoSmithKline, LLC. | ZEJULA (Drug) | Travel and Lodging | In-kind items and services | $276.64 | General |
| Category: ONCOLOGY | ||||||
| 12/11/2024 | GlaxoSmithKline, LLC. | ZEJULA (Drug) | Food and Beverage | In-kind items and services | $109.62 | General |
| Category: ONCOLOGY | ||||||
| 12/10/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Travel and Lodging | In-kind items and services | $288.47 | General |
| Category: Oncology | ||||||
| 12/10/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $117.27 | General |
| Category: Oncology | ||||||
| 12/09/2024 | GlaxoSmithKline, LLC. | ZEJULA (Drug) | Travel and Lodging | In-kind items and services | $146.48 | General |
| Category: ONCOLOGY | ||||||
| 12/09/2024 | GlaxoSmithKline, LLC. | ZEJULA (Drug) | Food and Beverage | In-kind items and services | $120.85 | General |
| Category: ONCOLOGY | ||||||
| 11/22/2024 | Genmab U.S., Inc. | Tivdak (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,625.00 | General |
| Category: Oncology | ||||||
| 11/19/2024 | GlaxoSmithKline, LLC. | JEMPERLI (Biological) | Travel and Lodging | In-kind items and services | $329.96 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF NIRAPARIB MAINTENANCE TREATMENT IN PATIENTS WITH HRD-POSITIVE ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY | TESARO, Inc. | $666.00 | 6 |
| A STUDY OF NIRAPARIB IN PATIENTS WITH OVARIAN CANCER WHO HAVE RECEIVED AT LEAST THREE PREVIOUS CHEMOTHERAPY REGIMENS | TESARO, Inc. | $600.00 | 4 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 306 | 434 | $262,645 | $70,440 |
| 2022 | 4 | 299 | 462 | $191,845 | $60,103 |
| 2021 | 6 | 354 | 548 | $325,041 | $89,815 |
| 2020 | 7 | 394 | 606 | $339,348 | $84,661 |
Total Patients
1,353
Total Services
2,050
Medicare Billing
$305,020
Procedure Codes
23
All Medicare Procedures & Services
23 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 55 | 131 | $64,059 | $21,318 | 33.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 84 | 113 | $41,132 | $13,042 | 31.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 65 | 65 | $45,305 | $12,220 | 27.0% |
| 58571 | Removal of uterus, tubes, and/or ovaries through abdomen using an endoscope, 250.0 g or less | Facility | 2023 | 14 | 14 | $55,593 | $11,093 | 20.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 77 | 100 | $24,700 | $7,843 | 31.8% |
| 38572 | Removal of lymph nodes of both sides of pelvis and abdominal lymph node biopsy using an endoscope | Facility | 2023 | 11 | 11 | $31,856 | $4,925 | 15.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 70 | 160 | $76,000 | $25,143 | 33.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 80 | 125 | $44,125 | $13,779 | 31.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 68 | 68 | $45,560 | $13,307 | 29.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 81 | 109 | $26,160 | $7,875 | 30.1% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 70 | 153 | $70,533 | $25,386 | 36.0% |
| 58571 | Abdominal removal of uterus (250 grams or less) with removal of tubes and/or ovaries using an endoscope | Facility | 2021 | 24 | 24 | $84,987 | $18,448 | 21.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 78 | 138 | $47,334 | $15,819 | 33.4% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 69 | 69 | $44,850 | $13,698 | 30.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 101 | 152 | $35,416 | $11,608 | 32.8% |
| 38572 | Removal of total lymph nodes of both sides of pelvis and abdominal lymph node biopsy using an endoscope | Facility | 2021 | 12 | 12 | $41,921 | $4,856 | 11.6% |
| 58571 | Abdominal removal of uterus (250 grams or less) with removal of tubes and/or ovaries using an endoscope | Facility | 2020 | 27 | 27 | $94,962 | $17,550 | 18.5% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 62 | 134 | $58,960 | $16,529 | 28.0% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 80 | 80 | $49,760 | $14,689 | 29.5% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 71 | 134 | $44,086 | $12,636 | 28.7% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 132 | 196 | $44,100 | $12,119 | 27.5% |
| 38572 | Removal of total lymph nodes of both sides of pelvis and abdominal lymph node biopsy using an endoscope | Facility | 2020 | 11 | 11 | $40,016 | $8,837 | 22.1% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 11 | 24 | $7,464 | $2,300 | 30.8% |
About Dr. John Chan, MD
Dr. John Chan, MD is a Obstetrics & Gynecology healthcare provider based in San Francisco, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/03/2006. The National Provider Identifier (NPI) number assigned to this provider is 1962596551.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Chan, MD has received a total of $2.1M in payments from pharmaceutical and medical device companies, with $336,565 received in 2024. These payments were reported across 1,612 transactions from 22 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.5M).
As a Medicare-enrolled provider, Chan has provided services to 1,353 Medicare beneficiaries, totaling 2,050 services with total Medicare billing of $305,020. Data is available for 4 years (2020–2023), covering 23 distinct procedure/service records.
Ad
Practice Information
- Specialty Obstetrics & Gynecology
- Other Specialties Gynecologic Oncology
- Location San Francisco, CA
- Active Since 10/03/2006
- Last Updated 05/28/2020
- Taxonomy Code 207V00000X
- Entity Type Individual
- NPI Number 1962596551
Products in Payments
- LYNPARZA (Drug) $696,946
- ZEJULA (Drug) $446,883
- Rubraca (Drug) $174,975
- JEMPERLI (Biological) $155,680
- Lenvima (Drug) $121,497
- TIVDAK (Biological) $96,795
- GARDASIL (Biological) $90,642
- Avastin (Biological) $68,642
- ELAHERE (Drug) $49,785
- Tivdak (Drug) $35,529
- KEYTRUDA (Biological) $24,607
- Elahere (Biological) $18,425
- TECENTRIQ (Biological) $18,199
- TIVDAK (Drug) $11,632
- myChoice CDx (Device) $4,430
- GARDASIL 9 (Biological) $3,355
- MYCHOICE CDX (Device) $862.50
- Harmonic (Device) $316.77
- PRECISETUMOR (Device) $269.87
- TAZVERIK (Drug) $224.95
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Obstetrics & Gynecology Doctors in San Francisco
Dr. Maida Taylor, Md, MD
Obstetrics & Gynecology — Payments: $279,575
Obstetrics & Gynecology $279,575
Dr. Linda Giudice, M.d, M.D
Obstetrics & Gynecology — Payments: $101,711
Obstetrics & Gynecology $101,711
Dr. Monica Pasternak, M.d, M.D
Obstetrics & Gynecology — Payments: $76,488
Obstetrics & Gynecology $76,488
Dr. Mitchell Rosen, M.d, M.D
Obstetrics & Gynecology — Payments: $51,468
Obstetrics & Gynecology $51,468
Michael Policar, Md Mph, MD MPH
Obstetrics & Gynecology — Payments: $40,331
Obstetrics & Gynecology $40,331
Philip Darney, Md, MD
Obstetrics & Gynecology — Payments: $36,014
Obstetrics & Gynecology $36,014